Clinical Trial Update: Effect of Symbicort ® on GR in Sputum in COPD [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update on the effect of Symbicort on gene expression in sputum for COPD.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Symbicort (budesonide/formoterol)

Snippet

Sponsor: Imperial College London | Conditions: Chronic Obstructive Lung Disease | Phase 4 | Status: COMPLETED | Results posted: 2020-11-23